August 2025 – Page 3

CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group

1 month ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Jr., medical groups, Policy, Robert F. Kennedy, staff exclusion, Vaccines, Working Group

CDC; ACIP; Covid-19; working group; staff exclusion; medical groups barred; vaccine policy; Robert F. Kennedy Jr.

Recent Advances: AI in Life Sciences—Reimagining Teams, Technology, and Partnerships

1 month ago talkbio0Tagged Artificial Intelligence, Biological Science Disciplines, Data Integration, Drug Discovery, Generative AI, language models, Precision Medicine, strategic partnerships, team transformation, technology innovation

AI in life sciences; generative AI; large language models; team transformation; technology innovation; strategic partnerships; drug discovery; personalized medicine; data integration

Who Is Making AI Work in Drug R&D in 2025?

1 month ago talkbio0Tagged Advice, Artificial Intelligence, Big Pharma, biopharma startups, Clinical Trials, Drug Development, Efficiency, Precision Medicine, United States Food and Drug Administration

AI drug discovery; Big Pharma; biopharma startups; clinical trials; FDA guidance; personalized medicine; drug development efficiency

Appia Bio Shuts Down Before Reaching Clinical Trials Amid Biotech Funding Crunch

1 month ago talkbio0Tagged Appia Bio, biotech closures, Cell Therapy, Clinical Trials, Indonesian language, Kite Pharma partnership, Neoplasms

Appia Bio; cell therapy; biotech shutdown; funding challenges; clinical trials; Kite Pharma partnership; oncology; biotech closures; IND application

Funding Drought Puts Pressure on Cell Therapy Startups Like Appia Bio

2 months ago talkbio0Tagged ACUA, Appia Bio, CAR-iNKT cells, Cell Therapy, Droughts, financing characteristics, venture

Appia Bio; cell therapy; funding drought; biotech; venture capital; Series A financing; ACUA platform; CAR-iNKT cells

Novartis Pays $30M Upfront to Leqembi Creator BioArctic for Access to Blood-Brain Barrier Technology

2 months ago talkbio0Tagged Antibodies, BioArctic, Blood - brain barrier anatomy, BrainTransporter platform, Leqembi, milestone payments, Nerve Degeneration, Novartis, Partnership, royalties

Novartis; BioArctic; BrainTransporter platform; blood-brain barrier; neurodegeneration; Leqembi; partnership; antibody; milestone payments; royalties

Lilly to Seek Global Approval for GLP-1 Pill After Obesity and Diabetes Trial Success

2 months ago talkbio0Tagged Approved, Clinical Trials, Contraceptives, Oral, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Glucagon-Like Peptide 1, Obesity, orforglipron, United States Food and Drug Administration, Weight Loss

Eli Lilly; GLP-1 pill; orforglipron; obesity; type 2 diabetes; FDA approval; weight loss; clinical trial

Regeneron Reports Phase 3 Success for Cemdisiran in Rare Disease Generalized Myasthenia Gravis

2 months ago talkbio0Tagged Alnylam, cemdisiran, Infrequent, Myasthenia Gravis, Generalized, Regeneron, regulatory submission, RNA drug, RNA, Small Interfering, United States

Regeneron; Phase 3 trial; cemdisiran; generalized myasthenia gravis; rare disease; RNA drug; siRNA; Alnylam Pharmaceuticals; U.S. regulatory submission

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

2 months ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

Akeso, Summit’s PD-1xVEGF Drug Ivonescimab Shows Strong Progression-Free Survival Benefit in Global Lung Cancer Trial

2 months ago talkbio0Tagged Akeso, Antibodies, Bispecific, Approved, Ivonescimab, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Phase 3 trial, Progression-Free Survival, summit, United States Food and Drug Administration

Akeso; Summit Therapeutics; ivonescimab; PD-1xVEGF; bispecific antibody; non-small cell lung cancer; progression-free survival; Phase 3 trial; overall survival; FDA approval